Hormones and Jawline: What the Evidence Shows

Hormones can change facial soft tissue, but the evidence does not establish a testosterone, DHT or estradiol target for creating a sharper jawline. A face photo cannot diagnose a hormone deficiency or tell you how to adjust a prescription.

This article replaces earlier unsupported claims about precise hormone targets, predictable cheek-fat loss and switching hair-loss medicines for facial definition. Sources were reviewed October 6, 2026. Prescribed hormone treatment can have important medical benefits; an unsupported cosmetic protocol is a different question.

What facial studies actually measure#

A 2019 single-centre cohort followed 27 transgender women and 15 transgender men receiving gender-affirming hormone treatment, with three-dimensional facial imaging at baseline, three months and one year. The authors reported changes in facial soft tissue, including increased cheek tissue in transgender women and a tendency toward reduced cheek tissue in transgender men. They also reported measurement limitations involving landmark reliability and facial positioning. Original study abstract.

A newer 2025 longitudinal study also used surface imaging to examine regional facial-volume changes during gender-affirming treatment. Its reported patterns varied by region and treatment group. Original study abstract.

These are useful human observations, but they are not trials of testosterone or antiandrogens prescribed to otherwise healthy adults seeking a particular jawline. Surface-volume changes do not, by themselves, identify changes in a specific fat pad, masseter muscle or jaw bone. The abstracts do not establish that a given drug will produce a predictable aesthetic result for an individual. Full texts of these two facial studies were unavailable for this review, so we do not infer unreported tissue measurements or protocols.

Lower estradiol is not an evidence-based jawline goal#

In a 16-week experiment, researchers suppressed natural sex-hormone production in healthy men and assigned different testosterone-gel doses. A second cohort also received an aromatase inhibitor. The study assessed body composition, thigh muscle, strength and sexual function—not facial definition. Estrogen deficiency primarily accounted for increases in body fat, while androgen deficiency accounted for losses in lean mass and muscle measures; both affected sexual function. Finkelstein and colleagues, full methods and results.

The investigators cautioned that short-term experimental suppression differs from gradual changes over years and that a rigid hormone threshold poorly represents individual responses. This study cannot supply a cosmetic estradiol target. It also gives no basis for assuming that lowering estradiol will selectively remove cheek fat.

Do not use facial puffiness as a reason to start an aromatase inhibitor, increase testosterone or change a prescribed hormone regimen. New or persistent swelling deserves assessment of its cause; our facial-puffiness guide explains the distinction between appearance concerns and symptoms needing care.

Hair-loss treatment is not a jaw-shaping protocol#

Evidence about hair counts or blood DHT does not establish whether a medicine improves or worsens someone's jawline. An anecdote about facial “softening” is not enough to recommend replacing finasteride or dutasteride, adding another antiandrogen, or stopping necessary treatment.

Topical finasteride should not be described as confined to the scalp. FDA's safety alert states that bloodstream absorption through the skin is expected and describes reports of systemic adverse effects, local reactions and unintended transfer. Spontaneous reports cannot establish the frequency of those effects, but they contradict a promise of zero systemic risk. FDA topical-finasteride alert.

Use our topical-versus-oral finasteride evidence guide for formulation-specific questions. Research products such as RU58841 should not be presented as established, scalp-only substitutes. Nor should spironolactone prescribed for acne be treated as a predictable way to soften or sharpen the jaw. Discuss a suspected medication-related change with the prescriber, including its timing and other symptoms.

What warrants a hormone assessment?#

The Endocrine Society's July 2026 statement emphasizes symptoms, consistently low and accurately measured testosterone, and clinical assessment when diagnosing male hypogonadism. It does not recommend population screening of asymptomatic men. It also notes that symptoms such as low energy or libido have multiple possible causes. Current Society statement.

If you already receive TRT, gender-affirming treatment or an antiandrogen, review concerns with the clinician managing that treatment. Bring the medication list, the timing of the change and any relevant test results. Do not treat an online appearance rating as evidence that your treatment is failing or that your hormone levels need adjustment.

Assess the actual concern before choosing an intervention#

• A sudden or symptomatic change: seek an appropriate medical assessment instead of experimenting with hormone doses.
• A medication concern: discuss it with the prescriber; do not infer causation from photographs alone.
• Jaw pain, clicking or difficulty chewing: seek dental assessment. More chewing resistance does not identify the cause.
• A cosmetic concern without symptoms: compare photographs under consistent conditions and avoid promises of a specific drug-induced facial shape.

The separate gum-chewing evidence guide examines actual jaw-exercise trials. Neither whole-body muscle research nor hormone-related facial changes establish that combining chewing exercises with higher androgen exposure will safely build a more attractive jaw.